Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

LNTH-2401

Radiopharmaceutical · developed by Lantheus Medical Imaging

Phase 2/3 Most advanced trial
LNTH Developer
1 Registered trials

What is LNTH-2401?

[68Ga]-LNTH-2401 is a gallium-68 labeled agent administered to identify newly diagnosed prostate cancer.

Summary written with AI from the sources listed at the end of this page.

At a glance

Drug type
Radiopharmaceutical
Therapy area
Oncology
Developer
Lantheus Medical Imaging (LNTH)
FDA status
Investigational, not approved in the US. Most advanced trial: Phase 2/3

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT07831824 Phase 2/3 Prostate Cancer Recruiting LNTH

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Prostate Cancer

More from Lantheus Medical Imaging

Sources

Updated Oct 18, 2026. Something wrong or missing? Report it on the LNTH page.

Follow LNTH, the company behind LNTH-2401

See LNTH's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

LNTH catalysts and pipeline →
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.